Mutations of Glucocorticoid Receptor in Bilateral Adrenal Hyperplasia
NCT ID: NCT02810496
Last Updated: 2026-01-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
150 participants
INTERVENTIONAL
2012-04-02
2016-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Role of Glucocorticoid Receptor SNPs in Receptor Function and Metabolic Disease
NCT01143493
Prevalence of Pituitary Incidentaloma in Relatives of Patients With Pituitary Adenoma
NCT00598949
Gene Polymorphisms Influencing Steroid Synthesis and Action
NCT00485186
Personalized Genomic Research
NCT01294345
Search for New Genetic Causes of Hypercalcemia by Massively Parallel Sequencing of a Genes Panel
NCT02908542
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
patient
blood collection for mutation characterization
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
blood collection for mutation characterization
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patients with bilateral adrenal masses
Exclusion Criteria
* Protected by law
* Have obvious signs of Cushing's syndrome
* No progressive neoplastic disease
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CHU de Reims
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chu Reims
Reims, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Vitellius G, Delemer B, Caron P, Chabre O, Bouligand J, Pussard E, Trabado S, Lombes M. Impaired 11beta-Hydroxysteroid Dehydrogenase Type 2 in Glucocorticoid-Resistant Patients. J Clin Endocrinol Metab. 2019 Nov 1;104(11):5205-5216. doi: 10.1210/jc.2019-00800.
Vitellius G, Trabado S, Hoeffel C, Bouligand J, Bennet A, Castinetti F, Decoudier B, Guiochon-Mantel A, Lombes M, Delemer B; investigators of the MUTA-GR Study. Significant prevalence of NR3C1 mutations in incidentally discovered bilateral adrenal hyperplasia: results of the French MUTA-GR Study. Eur J Endocrinol. 2018 Apr;178(4):411-423. doi: 10.1530/EJE-17-1071. Epub 2018 Feb 14.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PN11010
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.